Please use this identifier to cite or link to this item: http://hdl.handle.net/11455/14215
標題: Melanoma antigen-A在犬正常及間質來源腫瘤組織的表現
Expression of Melanoma Antigen-A in Canine Normal and Mesenchymal Neoplastic Tissues
作者: 陳音竹
Chen, Yin-Chu
關鍵字: cancer/testis antigen
腫瘤睪丸抗原
MAGE-A
canine melanoma
黑色素細胞瘤抗原-A
狗黑色素細胞瘤
出版社: 獸醫學系暨研究所
引用: Aarntzen, E.H.J.G., Figdor, C.G., Adema, G.J., Punt, C.J.A., de Vries, I.J.M., 2008. Dendritic cell vaccination and immune monitoring. Cancer Immunol Immunother 57, 1559-1568. Ait-Tahar, K., Liggins, A.P., Collins, G.P., 2009. Cytolytic T-cell response to the PASD1 cancer testis antigen in patients with diffuse large B-cell lymphoma. Br J Haematol 146, 396-407. Amar-costesec, A., Godelaine, D., Stockert, E., Van der Bruggen, P., Beaufay, H., Chen, Y.T., 1994. The tumor protein MAGE-1 is located in the cytosol of human melanoma cells. Biochem biophys Res Comm 204, 710-715. Aronsohn, M.G., Carpenter, J.L., 1990. Distal extremity melanocytic nevi and malignant melanomas in dogs. J Am Anim Hosp Assoc 26, 605-612. Atanackovic, D., Altorki, N.K., Cao, Y., 2008. Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming. Proc Natl Acad Sci U S A 105, 1650-1655. Aubry, F., Satie, A.P., Rioux-Leclercq, N., Rajpert-De Meyts, E., Spagnoli, G.C., Chomez, P., De Backer, O., Jegou, B., Samson, M., 2001. MAGE-A4, a germ cell specific marker, is expressed differentially in testicular tumors. Cancer 92,2778-2785. Bai, S., He, B., Wilson, E.M., 2005. Melanoma antigen gene protein MAGE-11 regulates androgen receptor function by modulating the interdomain interaction. Mol Cell Biol 25, 1238-1257. Barker, P.A., Salehi, A., 2002. The MAGE proteins: emerging roles in cell cycle progression, apoptosis, and neurogenetic disease. Journal of Neuroscience Research 67, 705-712. Barrow, C., Browning, J., MacGregor, D., Davis, I.D., Sturrock, S., Jungbluth, A.A., Cebon, J., 2006. Tumor antigen expression in melanoma varies according to antigen and stage. Clin Cancer Res, 12, 764-771. Beck, E.R., Withrow, S.J., McChesney, A.E., Richardson, R.C., Henderson, R.A., Norris, A.M., Caywood, D.D., Klausner, J.S., Harvey, H.J., Holmberg, D.L., 1986. Canine tongue tumors: a retrospective review of 57 cases. J Am Anim Hosp Assoc 22, 525-532. Bolon, B., Calderwood-Mays, M.B., Hall, B.J., 1990. Characteristics of canine melanomas and comparison of histology and DNA ploidy to their biologic behavior. Vet Pathol 27, 96-102. Boon, T., 1987. Production of stable cytolytic T-cell clones directed against autologous human melanoma. Int J Cancer 39, 390-396. Boon, T., Old, L.J., 1997. Cancer tumour antigens. Curr Opin Immunol 9, 681-683. Boon, T., van der Bruggen, P., 1996. Human tumor antigens recognized by T lymphocytes. J Exp Med 183, 725-729. Borthwick, R., Else, R.W., Head, K.W., 1982. Neoplasia and allied conditions of the canine oropharynx. Vet Ann 22, 248-269. Bostock, D.E., 1979. Prognosis after surgical excision of canine melanomas. Vet Pathol 16, 32-40. Brantley, M.A.Jr., Harbour, J.W., 2000. Deregulation of the Rb and p53 pathways in uveal melanoma. Am J Pathol 157, 1795-1801. Brasseur, F., Rimoldi, D., Lienard, D., 1995. Expression of MAGE genes in primary and metastatic cutaneous melanoma. Int J Cancer 63, 375-380. Brodey, R.S., 1960. A clinical and pathologic study of 130 neoplasms of the mouth and pharynx in the dog. Am J Vet Res 21, 787-812. Busam, K.J., Jungbluth, A.A., 1999. Melan-A, a new melanocytic differentiation marker. Adv Anat Pathol 6, 12-18. Callender, G.R., 1931. Malignant melanotic tumors of the eye. A study of histologic types in 111 cases. Trans Am Acad Ophthalmol Otolaryngol 36, 131-142. Caballero, O.L., Chen, Y.T., 2009. Cancer⁄testis (CT) antigens: Potential targets for immunotherapy. Cancer Sci 32, 4340-4350. Chénier, S., Doré, M., 1999. Oral malignant melanoma with osteoid formation in a dog. Vet Pathol 36, 74-76. Chen, Y.T., Old, L.J., 1999. Cancer-testis antigens: targets for cancer immunotherapy. Cancer J Sci Am 5, 16-17. Chen, Y.T., Stockert, E., Tsang, S., Coplan, K.A., Old, L.J., 1995. Immunophenotyping of melanomas for tyrosinase: implications for vaccine development. Proc Natl Acad Sci USA 92, 8125-8129. Chomez, P., 2001. An overview of the MAGE gene family with the identification of all human members of the family. Cancer Res 61, 5544-5551. Conroy, J.D., 1967. Melanocytic tumors of domestic animals. Arch Dermatol 96, 372-380. Cotran, R.S., Kumar, V., Collins, T., 1999. The female breast. In: Robbins Pathological Basis of Disease, ed. Cotran RS, 6th ed., WB Saunders, Philadelphia, PA, 1093-1119. Davis, I.D., Chen, W., Jackson, H., 2004. Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proc Natl Acad Sci U S A 101, 10697-10702. De Las Casas, L.E., Raso, D.S., Baird, D.B., Silverman, J.F., 1998. FNA of malignant melanoma: a brown stain without brown stains? Diagn Cytopathol 19, 151-152. De Smet, C., Lurquin, C., Lethe, B., Martelange, V., Boon, T., 1999. DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter. Mol Cell Biol, 19: 7327-7335. Dunstan, R.W., Rosser, E.J., 1985. Comparative aspects of cutaneous melanocytic neoplasms in the dog. Comp Dermatopathol 7, 197-201. Eura, M., Ogi, K., Chikamatsu, K., Lee, K.D., Nakano, K., Masuyama, K., Itoh, K., Ishikawa, T., 1995. Expression of the MAGE gene family in human head-and-neck squamous-cell carcinomas Int J Cancer 20, 304-308. Frank, C., Hundemer, M., Ho, A.D., Goldschmidt, H., Witzens-Harig, M., 2008. Cellular immune responses against the cancer-testis antigen SPAN-XB in healthy donors and patients with multiple myeloma. Leuk Lymphoma 49, 779-785. Fukuyama, T., Hanagiri, T., Takenoyama, M., 2006. Identification of a new cancer ⁄ germline gene, KK-LC-1, encoding an antigen recognized by autologous CTL induced on human lung adenocarcinoma. Cancer Res 66, 4922-4928. Gaugler, B., 1994. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med 179, 921-930. Goldschmidt, M.H., 1985. Benign and malignant melanocytic neoplasms of domestic animals. Am J Dermatopathol 7, 203-212. Goldschmidt, M.H., Shofer, F.S., 1992. Skin Tumors of the Dog and Cat. Butterworth Heinemann, Oxford, UK, 142-151. Grimm, E.A., Mazumder, A., Zhang, H.Z., 1982. Lymphokine-activated killer cell phenomenon: Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med 155, 1823-1841. Gure, A.O., 2000. CT10: a new cancer-testis (CT) antigen homologous to CT7 and the MAGE family, identified by representational-difference analysis. Int J Cancer 85, 726-732. Gure, A.O., Chua, R., Williamson, B., Gonen, M., Ferrera, C.A., Gnjatic, S., Ritter, G., Simpson, A.J.G., Chen, Y.T., Old, L.J., Altorki, N.K., 2005. Cancer-testis genes are coordinately expressed and are markers of poor outcome in nonsmall cell lung cancer. Clin Cancer Res 11, 8055- 8062. Harvey, H.J., MacEwen, E.G., Braun, D., Patnaik, A.K., Withrow, S.J., Jongeward, S., 1981. Prognostic criteria for dogs with oral melanoma. J Am Vet Med Assoc 178, 580-582. Herin, M., Lemoine, C., Weynants, P., Vessiere, F., Van Pel, A., Knuth, A., Devos, Rimoldi, R., Salvi, S., Schultz-thater, E., Spagnoli, G., Cerorrini, J.C., 2000. Anti-MAGE-3 antibody 57B and anti-MAGE-1 antibody 6C1 can be used to study different proteins of the MAGE-A family. Int J Cancer, 86, 749-751. Hoyt, R.F., Withrow, S.J., 1984. Oral malignancy in the dog. J Am Anim Hosp Assoc 20, 83-92. Itoh, K., Hayashi, A., Masanobu, N., Hoshino, T., Seki, N., Shichijo, S., 1996. Human Tumor rejection antigens MAGE. J Biochem 119, 385-390. Jager, E., Karbach, J., Gnjatic, S., 2006. Recombinant vaccinia ⁄ fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients. Proc Natl Acad Sci USA 103, 14453-144538. Janitz, M., Fiszer, D., Michalczak-janitz, K., Lukaszyk, A., Fernandez, N., Skorupski, W., Kurpisz, M., 1994. Analysis of mRNA for class I HLA on human gametogenic cells. Mol Reprod Develop 38, 231-237. Jungbluth, A.A., Busam, K.J., Kolb, D., Iversen, K., Coplan, K., Chen, Y.T., Spangoli, G.C., Old, L.J., 2000. Expression of MAGE-antigens in normal tissues and cancer. Int J Cancer 85, 460-465. Jungbluth, A.A., Stockert, E., Chen, Y-T., Kolb, D., Iversen, K., Coplan, K., Williamson, B., Altorki, N., Busam, K.J., Old, L.J., 2000. Monoclonal antibody MA454 reveals a heterogeneous expression pattern of MAGE-1 antigen in formalin-fixed paraffin embedded lung tumours. British Journal of Cancer 83, 493-497. Jungbluth, A.A., Wilson, A., Silva Jr., Iversen, K., Frosina, D., Zaidi, B., Coplan, K., Eastlake-Wade, S.K., Castelli, S.B., Spagnoli, G.C., Old, L.J., Vogel, M., 2007. Expression of cancer-testis (CT) antigens in placenta. Cancer Immunity 24, 15-27. Kawakami, Y., Rosenberg, S.A., 1997. Human tumor antigens recognized by T-cells. Immunol Res 16, 313-339. Kirkwood, J.M., Ernstoff, M., 1985. Melanoma: Therapeutic options with recombinant interferons. Semin Oncol 12, 7-12. Krauss, E., & Rauthe, S., Gattenlöhner, S., Reuther, T., Kochel, M., Kriegebaum, U., Kübler, A.C., Müller-Richter, Urs.D.A., 2010. MAGE-A antigens in lesions of the oral mucosa. Clin Oral Invest DOI 10.1007/s00784-010-0387-9. Kocher, T., Schultz-thater, E., Gudat, F., Schaefer, C., Casorati, G., Juretic, A., Willimann, T., Harder, F., Heberer, M., Spagnoli,G.C., 1995. Identification and intracellular location of MAGE-3 gene product. Cancer Res 55, 2236-2239. Laduron, S., 2004. MAGE-A1 interacts with adaptor SKIP and the deacetylase HDAC1 to repress transcription. Nucleic Acids Res 32, 4340-4350. Lehmann, F.L.J., Gaulis, S., Gruselle, O., Brichard, V., 2008. Clinical Response to the MAGE-A3 Immunotherapeutic in Metastatic Melanoma Patients is associated with a Specific Gene Profile Present Prior to Treatment. XVIth meeting in the Cancer Research Institute International Cancer Immunotherapy Symposium Series and the 2008 Meeting of the Cancer Vaccine Consortium, 25. Marchand, M., van Baren, N., Weynants, P., 1999. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer 80, 219-230. Ma, Z., Khatlani, T.S., Ohno, K., Sasaki, K., Inokuma, H., Onishi, T., 2000. Cloning and sequencing of canine MAGE cDNA. Tissue Antigens 56, 166-169. McKnight, J.A., Mauldin, G.N., McEntee, M.C., 2000. Radiation treatment for incompletely resected soft-tissue sarcomas in dogs. J Am Vet Med Assoc 217, 205-210. Meklat, F., Li, Z., Wang, Z., Zhang, Y., Zhang, J., Jewell, A., Lim, S.H., 2007. Cancer-testis antigens in haematological malignancies. British Journal of Haematology 136, 769-776. Mellersh, C., 2008. Give a dog a genome. The Veterinary Journal 178, 46-52. Morten, F.G., Kirsten, K., Ole, N., Henrik, J.D., 2007. MAGE-A1, GAGE and NY-ESO-1 cancer/testis antigen expression during human gonadal development. Human Reproduction 22, 953-960. Muscatelli, F., Walker, A.P., De Plaen, E., Stafford, A.N., Monaco, A.P., 1995. Isolation and characterization of a MAGE gene family in the Xp21. 3 region. Proc Natl Acad Sci USA 92, 4987-4991. Nagao, T., Higashitsuji, H., Nonoguchi, K., 2003. MAGE-A4 interacts with the liver oncoprotein gankyrin and suppresses its tumorigenic activity. J Biol Chem 278, 10668-10674. Nakhleh, R.E., Wick, M.R., Rocamora, A., 1990. Morphologic diversity in malignant melanomas. Am J Clin Pathol 93, 731-740. Nelson, P.T., Zhang, P.J., Spagnoli, G.C., Tomaszewski, J.E., Pasha, T.L., Frosina, D., Caballero, O.L., Simpson, A.J.G., Old, L.J., Jungbluth, A.A., 2007. Cancer/testis (CT) antigens are expressed in fetal. Ovary Cancer Immunity 7, 1-7. Oakes, M.G., Lewis, D.D., Hedlund, C.S., Hosgood, G., 1993. Canine oral neoplasia. Comp Contin Educ Pract Vet 15, 15-30. Oi, S., Natsume, A., Ito, M., 2009. Synergistic induction of NY-ESO-1 antigen expression by a novel histone deacetylase inhibitor, valproic acid, with 5-aza-2 -deoxycytidine in glioma cells. J Neurooncol 92, 15-22. Old, L.J., 2001. Cancer ⁄ testis (CT) antigens - a new link between gametogenesis and cancer. Cancer Immun 1, 1-10. Old, L.J., Chen, Y.T., 1998. New paths in human cancer serology. J Exp Med 187, 1163-1167. Pearson, O.P., Enders, R.K., 1943. Ovulation, maturation and fertilization in the fox. Anat Rec 85, 69-83. Peikert, T., Specks, U., Farver, C., Erzurum, S.C., Comhair, S.A., 2006. Melanoma antigen A4 is expressed in non-small cell lung cancers and promotes apoptosis. Cancer Res 66, 4693-700. Pold, M., 1999. Identification of a new, unorthodox member of the MAGE gene family. Genomics 59, 161-167. Pulley, L.T., Stannard, A.A., 1990. Tumors of the skin and soft tissues. In: Tumors in Domestic Animals, ed. Moulton JE, 3rd ed., University of California Press, Berkeley and Los Angeles, CA, 75-82. Rabanal, R.H., Fondevila, D.M., Montané, V., Domingo, M., Ferrer, L., 1989. Immunocytochemical diagnosis of skin tumours of the dog with special reference to undifferentiated types. Res Vet Sci 47, 129-133. Ramos-vara, J.A., Beissenherz, M., Miller, M., Johnson, G.C., Pace, L.W., Fard, A., Kottler, S.J., 2000. Retrospective study of 338 canine oral melanomas with clinical, histologic, and immunohistochemical review of 129 Cases. Vet Pathol 37, 597-608. Redding, L., Weiner, D.B., 2009. DNA vaccines in veterinary use. Expert Rev Vaccines 8, 1251-1276. Sandusky, G.E., Carlton, W.W., Wightman, K.A., 1985. Immunohistochemical staining for S100 protein in the diagnosis of canine amelanotic melanoma. Vet Pathol 22, 577-581. Sandusky, G.E., Carlton, W.W., Wightman, K.A., 1987. Diagnostic immunohistochemistry of canine round cell tumors. Vet Pathol 24, 495-499. Scanlan, M.J., Simpson, A.J., Old, L.J., 2004. The cancer/testis genes: review, standardization, and commentary. Cancer Immun 4, 1-12. Schultz-thater, E., Juretic, D.P., Lüscher, U., Siegrist, W., Harder, F., Heberer, M., Zuber, M., Spagnoli, G.C., MAGE-1 gene product is a cytoplasmic protein. Int. J. Cancer 59, 435-439. Sigalotti, L., Fratta, E., Coral, S., 2004. Intratumor heterogeneity of cancer ⁄ testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2¢-deoxycytidine. Cancer Res 64, 9167-9171. Simpson, A.J.G., Caballero, O.L., Jungbluth, A., Chen, Y.T., Old, L.J., 2005. Cancer/testis antiens, gametogenesis and cancer. Nature Review Cancer 5, 615-625. Skrzypczak, J., Pisarski, T., Biczysko, W., Kedzia, H., 1981. Evaluation of germ cells development in gonads of human fetuses and newborns. Folia Histochem Cytochem 19, 17-24. Smith, S.H., Goldschmidt, M.H., Mcmanus, P.M., 2002. A comparative review of melanocytic neoplasms. Vet Pathol 39,651-678. Takahashi, K., Isobe, T., Ohtsuki, Y., Akagi, T., Sonobe, H., Okuyama, T., 1984. Immunohistochemical study on the distribution of a and b subunits of S-100 protein in human neoplasm and normal tissues. Virchows Arch 45, 385-396. Takahashi, K., Shichijo, S., Noguchi, M., Hirohata, M., Itoh, K., 1995. Identification of MAGE-1 and MAGE-4 proteins in spermatogonia and primary spermatocytes of testis. Cancer Res 55, 3478-3482. Todoroff, R.J., Brodey, R.S., 1979. Oral and pharyngeal neoplasia in the dog: a retrospective survey of 361 cases. J Am Vet Med Assoc 175, 567-571. Traversari, C., 1992. Transfection and expression of a gene coding for a human melanoma antigen recognized by autologous cytolytic T lymphocytes. Immunogenetics 35, 145-152. Van der Bruggen, P., 1991. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254, 1643-1647. Vourc'h-Jourdain, M., Volteau, C., Nguyen, J.M., Khammari, A., Dreno, B., 2009. Melanoma gene expression and clinical course. Arch Dermatol Res 301, 673-679. Weber, J., Salgaller, M., Samid, D., 1994. Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2¢-deoxycytidine. Cancer Res 54, 1766-1771. Weiss, E., Frese, K., 1974. Tumors of the skin. Bull World Health Organ 50:79-100. Xing, Q., Pang, X.W., Peng, J.R., 2008. Identification of new cytotoxic T-lymphocyte epitopes from cancer testis antigen HCA587. Biochem Biophys Res Commun 372, 331-335. Yang, B., O'Herrin, S.M., Wu, J., 2007. MAGE-A, mMage-b, and MAGE-C proteins form complexes with KAP1 and suppress p53-dependent apoptosis in MAGE-positive cell lines. Cancer Res 67, 9954-9962. Yang, B., O'Herrin, S., Wu, J., Reagan-Shaw, S., Ma, Y., Nihal, M., Longley, B.J., 2007. Select cancer testis antigens of MAGE-A, -B, and -C families are expressed in mast cell lines and promote cell viability in vitro and in vivo. J Invest Dermatol 127, 267-275. Yoshida, N., Abe, H., Ohkuni, T., Wakita, D., Sato, M., Noguchi, D., Miyamoto, M., Morikawa, T., Kondo, S., Ikeda, H., Nishimura, T., 2006. Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens and T cell infiltration in non-small cell lung carcinoma and their prognostic significance. Int J Oncol 28, 1089-1098.
摘要: 黑色素細胞瘤抗原-A (Melanoma antigen-A, MAGE-A)於1991年被發現,其包含12個相關抗原為MAGE-A1到MAGE-A12,這些抗原在人類組織中會少量且侷限的表現在正常組織中,如睪丸、胎盤、及胎兒性腺,在腫瘤方面,會被表現在多種腫瘤細胞上,此種抗原之表現特性適合作為免疫療法之標的抗原。然而,相關於狗MAGE-A的研究相當稀少,因此,本實驗目的為確立人類MAGE-A抗體6C1使用於犬組織的免疫組織化學染色流程、調查MAGE-A在犬正常組織及腫瘤組織之表現、以犬口腔黑色素瘤做一延伸,探討其表現與各種臨床特性、存活時間的相關性,並偵測MAGE-A亞型的表現。本實驗所用的抗體可偵測MAGE-A1, -A2, -A3, -A6, -A10, -A11, 及 -A12,在確立犬組織所適用的免疫組織化學染色流程後,總共偵測了18個正常組織、28個黑色素細胞瘤、32個口鼻腔惡性腫瘤(含口腔黑色素瘤)、40個圓形細胞瘤及37個軟組織肉瘤。此外,為了得知MAGE-A亞型在犬組織中的表現,聚合酵素鏈鎖反應中的引子可作用於MAGE-A基因中高度保留之區域,可藉由增幅出此高度保留片段,定序後經BLAST軟體比對,便可分型。免疫組織化學染色的結果顯示,所有正常組織包括皮膚、皮膚附屬器、齒齦、肌肉、脂肪組織、結締組織、唾液腺、淋巴結、小腸黏膜、乳腺、肝臟、軟骨、輸卵管、子宮內膜、大腦及小腦皆呈陰性,而睪丸的生殖細胞及卵巢的卵母細胞除外。於犬腫瘤中MAGE-A的表現會隨腫瘤類別不同而有差異,黑色素細胞瘤有75.00% (21/28) 的表現率,口鼻腔惡性腫瘤68.75% (22/32)的表現率,圓型細胞瘤52.50% (21/40)的表現率,軟組織肉瘤則有40.50% (15/37)的表現率。此外,分析一隻正常睪丸及九隻黑色素細胞瘤的犬隻所表現的MAGE-A亞型,正常睪丸的MAGE-A序列與人的MAGE-A2 (NM_005361)及狗的MAGE-A10 (XM_549339)最為相似,相似度分別為68.6%及91.4%,本實驗中十隻狗的MAGE-A序列彼此之相似度為71.7-95.3%。根據此抗原在犬正常組織中的侷限表現,且廣泛表現在多種腫瘤中的特性,以MAGE-A為標的抗原的免疫療法用來治療腫瘤已轉移或是腫瘤難以完全切除的犬隻,將有可能為一有治療潛力的輔助療法。
Melanoma antigen-A, MAGE-A, which contained 12 members from A1 to A12 was discovered since 1991. These antigens expressed in various types of tumors but limited expressed in normal human placentas and testicles. However, researches about MAGE-A in dogs were rare. The aims of this study were: first, to establish an immunohistochemistry protocol with MAGE-A antibody 6C1 for canine tissues. Second, to investigate the expression of MAGE-A in canine normal and neoplastic tissues. Third, concerning about canine melanoma, to investigate the expression of MAGE-A subtypes and the correlation between MAGE-A expression rate, clinical characteristics and surviving. Immunohistochemical staining with an antibody 6C1 against MAGE-A1, -A2, -A3, -A6, -A10, -A11, and -A12 was used to detect the expression of MAGE-A in 18 normal tissues, 26 melanomas, 5 nasal malignant tumors, 6 oral malignant tumors, 40 round cell tumors, and 37 soft tissue sarcomas. Besides, according to the highly conserved MAGE-A genes, a pair of primers were used to amplify the specific sequences of each subtype by PCR. The expression of each subtype was affirmed by DNA sequencing. According to our results, normal tissues including skin, skin adnexa, gingiva, muscle, adipose tissue, connective tissue, salivary gland, lymph node, intestine mucosa, mammary gland, liver, cartilage, oviduct, endometrium, cerebellum, and cerebrum showed the negative immunoreaction except for testicular germ cells and ovarian oocytes. The expression rate varied with the tumor type, 75.00% (21/28) of melanomas, 52.50% (21/40) of round cell tumors, and 40.50% (15/37) of soft tissue sarcomas showed the positive immunoreaction. Additionally, MAGE-A sequences from one normal testis and nine melanomas were analyzed. MAGE-A sequence from normal canine testis showed 68.6% identity with human MAGE-A2 (NM_005361) and 91.4% identity with canine MAGE-A10 (XM_549339). MAGE-A in canine testicle shared 71.7-95.3% of identities with canine melanoma sequences generated in this study. Based on its limited expression in canine normal tissues and widely expression in various types of canine mesenchymal tumors, MAGE-A might be used for antigen-specific cancer immunotherapy which was regarded as a promising treatment for metastasis cancer, or tumors which were difficult to be excised completely.
URI: http://hdl.handle.net/11455/14215
其他識別: U0005-1808201016462200
文章連結: http://www.airitilibrary.com/Publication/alDetailedMesh1?DocID=U0005-1808201016462200
Appears in Collections:獸醫學系所

文件中的檔案:

取得全文請前往華藝線上圖書館



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.